Just a few months after suggesting it may not survive to the end of 2023, Novavax has posted improved finances and a second-quarter profit, as it readies the launch of an
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centre
GSK has filed a lawsuit against Pfizer in a US court alleging infringement of patents that it holds on vaccines against respiratory syncytial virus (RSV).<
A potentially game-changing new vaccine for tuberculosis is set for a major clinical trials programme, thanks to $550 million in funding from philanthropic organisations t
The FDA has given a fast-track designation to a gonorrhoea vaccine in development at GSK that could help turn the tide of the sexually-transmitted infection, which is on t
While at Reuters Pharma Europe in Barcelona the other week, pharmaphorum web editor Nicole Raleigh spoke with Florian Schnappauf, VP of enterprise commercial strategy at Veeva Europe, about
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.